Last reviewed · How we verify

AZD1419 — Competitive Intelligence Brief

AZD1419 (AZD1419) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiopoietin-2 decoy receptor. Area: Ophthalmology.

phase 2 Angiopoietin-2 decoy receptor Ang-2 decoy receptor Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

AZD1419 (AZD1419) — AstraZeneca. AZD1419 is a recombinant human angiopoietin-2 (Ang-2) decoy receptor.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
AZD1419 TARGET AZD1419 AstraZeneca phase 2 Angiopoietin-2 decoy receptor Ang-2 decoy receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Angiopoietin-2 decoy receptor class)

  1. AstraZeneca · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AZD1419 — Competitive Intelligence Brief. https://druglandscape.com/ci/azd1419. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: